We have witnessed a reduction in ALND, but the recent monarchE trial confirmed the benefit of CDK4/6 inhibitors in patients with four or more metastatic lymph nodes and HR+ breast cancer, interfering with the trend in axillary surgery de-escalation [7]. The gene discussed is CDK4; the disease is breast carcinoma.